Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
| ▸ | RAB9A | P51151 | 3/20 | 0.72 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 6/20 | 0.48 |
| ▸ | MMP2 | P08253 | 5/20 | 0.48 |
| ▸ | MMP1 | P03956 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11703618 | 0.96 | MAPT (0.78) | MAPTNPC1RAB9AMRGPRX4PTGDR2 | |
| SCHEMBL3568125 | 0.89 | MAPT (0.56) | MAPTNPC1RAB9APPARDHSP90AA1 | |
| SCHEMBL14302573 | 0.87 | MAPT (0.54) | MAPTNPC1RAB9APPARDHSP90AA1 | |
| SCHEMBL3558198 | 0.87 | MAPT (0.67) | MAPTNPC1RAB9APPARDHSP90AA1 | |
| SCHEMBL3560701 | 0.87 | MAPT (0.54) | MAPTNPC1RAB9AHSP90AA1MMP13 | |
| SCHEMBL3555592 | 0.87 | MAPT (0.57) | MAPTNPC1RAB9APPARDHSP90AA1 | |
| SCHEMBL4444835 | 0.85 | MAPT (0.52) | MAPTNPC1RAB9APPARDHSP90AA1 | |
| SCHEMBL4446197 | 0.85 | MMP13 (0.53) | MAPTNPC1RAB9APPARDHSP90AA1 | |
| SCHEMBL13816246 | 0.84 | MAPT (0.55) | MAPTNPC1RAB9AHSP90AA1MMP13 | |
| SCHEMBL1574830 | 0.84 | MAPT (1.00) | MAPTNPC1RAB9AMRGPRX4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | claimed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1663936-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005000781-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE AG | 2004-12-30 | — | — | US | claimed |
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG AN | 2008-10-16 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1663936-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005000781-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE AG | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | GYS2, GYS1, PYGL | MAPT 3129/4885NPC1 1101/4885RAB9A 4007/4885 |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | MAPT 3141/4885NPC1 1670/4885RAB9A 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.